Posted by Michael Wonder on 26 Mar 2024
Johnson & Johnson's nipocalimab granted US FDA fast track designation to reduce the risk of foetal neonatal allo-immune thrombocytopenia in allo-immunised pregnant adults
26 March 2024 - The Phase 3 FREESIA program is underway and nipocalimab is the only investigational therapy currently reported to be in clinical development for the treatment of FNAIT.
Johnson & Johnson announced today that the US FDA has granted fast track designation for nipocalimab to reduce the risk of FNAIT in allo-immunised pregnant adults during their current pregnancy.
